2018
A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
Weber JS, Sznol M, Sullivan RJ, Blackmon S, Boland G, Kluger HM, Halaban R, Bacchiocchi A, Ascierto PA, Capone M, Oliveira C, Meyer K, Grigorieva J, Asmellash SG, Roder J, Roder H. A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma. Cancer Immunology Research 2018, 6: 79-86. PMID: 29208646, DOI: 10.1158/2326-6066.cir-17-0412.Peer-Reviewed Original ResearchConceptsAcute phase reactantsCheckpoint inhibitorsOverall survivalPhase reactantsIpilimumab-treated patientsPD-1 blockadeTrials of nivolumabBetter overall survivalIndependent patient cohortsPretreatment serumPD-1Melanoma patientsValidation cohortMetastatic melanomaMultipeptide vaccinePatient cohortPooled analysisWorse outcomesClinical dataPatientsMultivariate analysisComplement cascadeMass spectrometry analysisNivolumabCohort
2006
Association between pathways in regulatory networks
Kluger Y, Kluger H, Tuck D. Association between pathways in regulatory networks. Annual International Conference Of The IEEE Engineering In Medicine And Biology Society (EMBC) 2006, 2006: 2036-2040. PMID: 17946929, DOI: 10.1109/iembs.2006.260730.Peer-Reviewed Original ResearchConceptsRegulatory networksCo-regulated pathwaysHuman regulatory networkRegulatory network connectivityDistinct cell typesTranscriptional regulatory levelCondition-specific networksGene regulationIndividual genesCell statesTranscriptional activityCell typesCell progressionExpression signaturesNumerous pathwaysGene profilesRemarkable connectivityMultiple pathwaysPathwayGenesRegulatory levelsRegulationExpressionCellsNotable differences